Promising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating Analysis

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Carisma Therapeutics (CARM – Research Report). The associated price target remains the same with $10.00.

Naureen Quibria’s rating is based on a comprehensive assessment of Carisma Therapeutics’ clinical developments and potential in cancer immunotherapy. The company’s pioneering work on CAR-engineered macrophages (CAR-M), particularly its lead therapeutic, CT-0508, aimed at HER-2 targeted CAR-M for solid tumors, shows promising therapeutic implications. The initial clinical data presented at AACR, despite being limited to a single case study, provided encouraging results that suggest CT-0508’s efficacy, especially when used in combination with anti-PD-1 therapy.
Furthermore, Quibria finds the safety profile of the combination therapy comparable to the monotherapy, enhancing its appeal. The case study demonstrated stable disease in a patient with a significant history of treatment resistance, indicating CT-0508’s potential to benefit patients with few remaining options. The observed lesion control, T-cell exhaustion, and clonality changes are indicative of anti-tumor activity, reinforcing the analyst’s optimistic outlook on the stock and supporting the Buy rating.

Quibria covers the Healthcare sector, focusing on stocks such as ADC Therapeutics, Carisma Therapeutics, and Fennec Pharmaceuticals. According to TipRanks, Quibria has an average return of -20.8% and a 23.58% success rate on recommended stocks.

In another report released yesterday, BTIG also initiated coverage with a Buy rating on the stock with a $6.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Carisma Therapeutics (CARM) Company Description:

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.